GILD·Nasdaq·US

Gilead Sciences

Gilead Sciences is a U.S. biopharmaceutical company focused on discovering, developing, and commercializing medicines in HIV, liver disease, and oncology. Its revenue is dominated by HIV products, with additional sales from liver disease therapies, oncology drugs, and cell therapy products.

Create free account

Recent Activity

Updated Oct 24, 2026

–BioNTech entered a clinical trial collaboration with Gilead Sciences to evaluate pumitamig in combination with Gilead's TROP2-directed antibody-drug conjugate sacituzumab govitecan in a Phase 3 trial for patients with PD-L1 low or negative triple-negative breast cancer.

Past updates are part of the Pro plan.

Thematic Position

GILD

Healthcare Innovation

Biotechnology

Cell TherapyLeader

Relationship Groups

Suppliers5

Customers3

Partners11

Licensing12

Competitors16

Relationship details are part of the Pro plan.

Recent Discoveries

Recent discoveries are part of the Pro plan.

Ended Relationships

11 ended relationships · Ended relationships are part of the Pro plan.

Management Perspective on Regulatory & Geopolitical Developments

price controltariffstate aid

IRA requires HHS to negotiate Medicare prices for Biktarvy starting 2028

SEC 10-KFeb 24, 2026

The full regulatory passage is part of the Pro plan.

15 more · Regulatory and geopolitical insights are part of the Pro plan.

Disclosed customers above 10% of revenue

3 customers · Named major customers are part of the Pro plan.